Apolipoprotein C-III Deficiency
|
0.610 |
GeneticVariation
|
disease |
BEFREE |
D25V apolipoprotein C-III is a new human amyloidogenic protein and the first conferring cardioprotection even in the unfavourable context of renal failure, extending the evidence for an important cardiovascular protective role of apolipoprotein C-III deficiency.
|
26790392 |
2016 |
Apolipoprotein C-III Deficiency
|
0.610 |
GeneticVariation
|
disease |
UNIPROT |
Apolipoprotein C-III(Lys58----Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia.
|
2022742 |
1991 |
Apolipoprotein C-III Deficiency
|
0.610 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
Apolipoprotein C-III Deficiency
|
0.610 |
Biomarker
|
disease |
CTD_human |
|
|
|
Hypercholesterolemia
|
0.460 |
Biomarker
|
disease |
BEFREE |
Vitamin D supplementation significantly increased total cholesterol, triglycerides, very-low-density lipoprotein (VLDL) triglycerides, low-density lipoprotein (LDL) triglycerides, high-density lipoprotein (HDL) triglycerides, apolipoprotein B (ApoB), LDL-ApoB, ApoCII, ApoCIII, phospholipids, and ApoE (P < .05 for all).
|
29653812 |
2019 |
Hypercholesterolemia
|
0.460 |
Biomarker
|
disease |
BEFREE |
About 80 genes are associated with hypercholesterolemia but only pharmaceuticals that inhibit cholesteryl ester transfer protein (CETP), angiopoietin-related protein 3 (ANGPTL3), and apolipoprotein C-III (apoC-III) have recently been tested in clinical trials.
|
29356705 |
2018 |
Hypercholesterolemia
|
0.460 |
Biomarker
|
disease |
BEFREE |
This study shows the relevance of polymorphisms in APOB (odds ratio (OR), 1.17; 95% confidence interval (95% CI), 0.74-1.85), APOC3 (OR, 1.33; 95% CI, 0.82-2.17) and APOE (OR, 1.75; 95% CI, 1.09-2.80), as genetic risk markers for hypercholesterolemia; polymorphisms in ACE (OR, 1.68; 95% CI, 0.32-8.77) and AGT (OR, 1.74; 95% CI, 0.97-3.14) for hypertension; and in APOE*3/*4 (OR, 2.06; 95% CI, 1.70-2.51) and APOE*4/*4 (OR, 3.08; 95% CI, 1.85-5.12) as unambiguous markers of dementia.
|
29081697 |
2017 |
Hypercholesterolemia
|
0.460 |
GeneticVariation
|
disease |
BEFREE |
Hypercholesterolemia is associated with the apolipoprotein C-III (APOC3) genotype in children receiving HAART: an eight-year retrospective study.
|
22848358 |
2012 |
Hypercholesterolemia
|
0.460 |
GeneticVariation
|
disease |
BEFREE |
Multivariate logistic regression analysis with adjustment for age, body mass index, and the prevalence of smoking, hypertension, diabetes mellitus, and hyperuricemia revealed that three polymorphisms [994G --> T (Val279Phe) in the platelet-activating factor acetylhydrolase gene, 242C --> T (His72Tyr) in the NADH/NADPH oxidase p22 phox gene, and 1100C --> T in the apolipoprotein C-III gene] were significantly associated with CAD in men with hypercholesterolemia.
|
14709372 |
2004 |
Hypercholesterolemia
|
0.460 |
Biomarker
|
disease |
BEFREE |
Hypercholesterolemics, in contrast, were distinguished from the normolipidemic group by 2-fold higher concentrations of apoB lipoproteins without apoE or apoC-III (E(-)C-III(-)), mainly LDL, which had high cholesterol content.
|
11483625 |
2001 |
Hypercholesterolemia
|
0.460 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
Hypercholesterolemia
|
0.460 |
Biomarker
|
disease |
HPO |
|
|
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Therefore, there appears to be a need for effective TG-lowering agents.<b>Areas covered</b>: This review presents the most recent advances in hypertriglyceridemia treatment; specifically, it discusses the results of clinical trials and critically comments on apolipoprotein C-III inhibitors, angiopoietin-like 3 inhibitors, alipogene tiparvovec, pradigastat, pemafibrate and novel formulations of omega-3 fatty acids.<b>Expert opinion</b>: In the era of extreme lowering of LDL-C levels with several agents, there seems to be space for novel therapeutic options to combat parameters responsible for residual CVD risk, among which are elevated TGs.
|
31738617 |
2020 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Furthermore, apoC-III and ANGPTL3, both of which are now known to associate with increased atherosclerotic cardiovascular diseases, were enriched in patients with CETP-D compared with normolipidemic subjects (35.9 ± 5.3 vs 27.1 ± 3.7, 2.3 ± 1.1 vs 0.4 ± 1.1, respectively; P < .01).
|
30745272 |
2020 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
In addition, apoC-III has also more recently been identified as an important risk factor for cardiovascular disease.
|
31111320 |
2019 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Is APOC3 the driver of cardiovascular disease in people with type I diabetes mellitus?
|
31449060 |
2019 |
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Conclusions HDL particles of larger size and higher concentrations of large HDL and of HDL without apolipoprotein C-III were associated with lower CVD risk, with risk estimates seemingly stronger among participants with lower eGFR.
|
31818211 |
2019 |
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
When put in the context of studies demonstrating significant protection from cardiovascular events in individuals with loss of function variants in the APOC3 gene, our results provide strong evidence that therapies which increase the efficiency of conversion of VLDL to LDL, thereby reducing remnant concentrations, should reduce the risk of cardiovascular disease.
|
30580564 |
2019 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Because serum levels of APOC3 predicted incident CVD events in the CACTI study, inhibiting APOC3 might reduce CVD risk in T1DM patients.
|
31295146 |
2019 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
ApoCIII and triglyceride (TG)-rich lipoproteins (TRL), particularly, large TG-rich lipoproteins particles, have been described as important mediators of cardiovascular disease (CVD) risk.
|
31247940 |
2019 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study.
|
30249512 |
2019 |
Coronary Arteriosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
It is effective in decreasing triglycerides by targeting apoC3 levels in patients with coronary heart disease.
|
30511426 |
2019 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Emerging evidences for the opposite role of apolipoprotein C3 and apolipoprotein A5 in lipid metabolism and coronary artery disease.
|
31836003 |
2019 |
Coronary Arteriosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Elevated apolipoprotein C-III (apoC-III) levels are associated with hypertriglyceridaemia and coronary heart disease.
|
31329855 |
2019 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
These impactful mouse studies were supported by the initial finding that APOC3 predicted coronary artery disease events in participants of the prospective Coronary Artery Calcification in Type 1 Diabetes study with normal TG levels.
|
31449060 |
2019 |